

Antipsychotic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Application (Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, Others), By Drug Classification(First Generation (Typical), Second Generation (Atypical)) By Company (2022) By Region and Competition

<https://marketpublishers.com/r/AFC25D1FCFCCEN.html>

Date: October 2023

Pages: 177

Price: US\$ 4,500.00 (Single User License)

ID: AFC25D1FCFCCEN

Abstracts

Global Antipsychotic Drugs Market has valued at USD 13.03billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 7.37% through 2028. The Antipsychotic Drugs market is a dynamic and crucial segment of the pharmaceutical industry, catering to individuals suffering from severe mental health conditions, such as schizophrenia, bipolar disorder, and treatment-resistant depression. These drugs play a pivotal role in managing the symptoms of these disorders, allowing patients to lead more fulfilling lives. Antipsychotic drugs, also known as neuroleptics, are a class of medications primarily used to manage psychiatric conditions like schizophrenia, bipolar disorder, and severe agitation. These drugs have played a crucial role in improving the quality of life for millions of people worldwide. However, their use is not without challenges, as they often come with side effects and require careful monitoring. The primary purpose of antipsychotic drugs is to alleviate the debilitating symptoms of conditions like schizophrenia. These symptoms include hallucinations, delusions, disorganized thinking, and severe mood swings. By altering the balance of certain neurotransmitters in the brain, particularly dopamine, antipsychotics can help stabilize a person's mental state and reduce the intensity and frequency of psychotic episodes. First and foremost, the prevalence of mental health disorders has been steadily increasing worldwide. Factors such as stress, lifestyle changes, and societal pressures have contributed to the rising incidence of conditions that require

antipsychotic medications. This growing patient population fuels the demand for these drugs, making the Antipsychotic Drugs market a robust and vital sector of the pharmaceutical industry. Moreover, ongoing research and development efforts in the field of mental health have led to the introduction of novel antipsychotic drugs. These newer medications often offer improved efficacy and a more favorable side-effect profile compared to their predecessors. As a result, healthcare providers are increasingly inclined to prescribe these newer, more advanced antipsychotic drugs, further driving market growth. Additionally, the global shift towards a greater awareness of mental health issues has reduced the stigma associated with seeking treatment. This cultural change has encouraged individuals to seek professional help, leading to higher diagnosis rates and greater demand for antipsychotic drugs.

Key Market Drivers

Rising Prevalence of Mental Health Disorders

One of the primary drivers of the Antipsychotic Drugs market is the increasing prevalence of mental health disorders globally. Conditions such as schizophrenia, bipolar disorder, and major depressive disorder affect millions of individuals worldwide. The growing awareness of mental health issues has led to higher diagnosis rates and a subsequent increase in the demand for antipsychotic medications to manage these conditions effectively. The rising prevalence of mental health disorders is a significant driver behind the growth of the Antipsychotic Drugs market. Mental health conditions have become increasingly common worldwide, affecting millions of individuals across all age groups. This surge in the incidence of disorders such as schizophrenia, bipolar disorder, major depressive disorder, and others has created a growing demand for effective treatments, including antipsychotic medications. The global burden of mental health disorders has been steadily increasing for several reasons. Modern lifestyles, increased stressors, and societal pressures have contributed to the rise in mental health issues. Additionally, improved diagnostic tools and greater awareness of mental health have led to more accurate diagnoses, further highlighting the need for effective treatments. Antipsychotic drugs are a cornerstone in the management of severe mental health disorders. They play a pivotal role in alleviating the debilitating symptoms associated with conditions like schizophrenia, including hallucinations, delusions, disorganized thinking, and mood disturbances. By targeting specific neurotransmitter systems, particularly dopamine, antipsychotic drugs help stabilize a patient's mental state, allowing them to lead more fulfilling lives. Furthermore, the reduction in stigma surrounding mental health has encouraged individuals to seek professional help. This cultural shift has led to higher diagnosis rates and increased patient volumes, further

fueling the demand for antipsychotic medications. People are more willing to discuss their mental health concerns openly and seek treatment, ultimately benefiting from the availability of effective antipsychotic drugs.

Advancements in Drug Development

The pharmaceutical industry has witnessed notable advancements in the development of antipsychotic drugs. Research efforts have led to the creation of newer, more efficacious medications with improved safety profiles. These innovative drugs offer enhanced treatment options for patients and drive market growth as healthcare providers increasingly turn to these advanced therapies. Advancements in drug development have been instrumental in propelling the Antipsychotic Drugs market forward, driving innovation and improving treatment outcomes for individuals with severe mental health disorders. These advancements have had a profound impact on the efficacy and safety profiles of antipsychotic medications, making them more effective tools in managing conditions such as schizophrenia, bipolar disorder, and major depressive disorder. One of the most significant contributions to the field of antipsychotic drugs has been the development of 'atypical' or second-generation antipsychotics. These newer medications represent a leap forward in terms of efficacy and side-effect profiles compared to their first-generation counterparts. Atypical antipsychotics like risperidone, aripiprazole, and olanzapine offer better control of symptoms while reducing the risk of movement disorders such as tardive dyskinesia, a common concern with first-generation antipsychotics.

Advancements in drug development have also led to the creation of long-acting injectable formulations of antipsychotic medications. These formulations offer several advantages, including improved adherence to treatment and a consistent, controlled release of the drug over an extended period. This helps ensure that patients receive the necessary medication and experience fewer fluctuations in symptom control.

Reducing Stigma and Increased Mental Health Awareness

Societal attitudes toward mental health have evolved, leading to reduced stigma associated with mental health conditions. People are now more open to seeking help for their mental health issues, resulting in higher patient volumes and greater demand for antipsychotic drugs. Increased awareness campaigns and advocacy have played a crucial role in reducing stigma. Reducing stigma and increased mental health awareness have played pivotal roles in boosting the Antipsychotic Drugs market. These societal shifts have not only encouraged individuals to seek help for their mental health

issues but have also led to greater recognition of the importance of effective treatments, including antipsychotic medications. Historically, mental health conditions carried significant stigma, often causing individuals to suffer in silence and avoid seeking professional help. However, in recent years, concerted efforts have been made to destigmatize mental health disorders. High-profile advocacy campaigns, media coverage, and personal stories shared by public figures have all contributed to changing perceptions and fostering a more empathetic and understanding society. Reduced stigma has led to increased mental health awareness, with more people acknowledging the prevalence and impact of conditions like schizophrenia, bipolar disorder, and major depressive disorder. As a result, more individuals are seeking help and receiving timely diagnoses, which, in turn, drives the demand for effective treatments, including antipsychotic drugs.

Furthermore, this cultural shift has encouraged open conversations about mental health within families, communities, and workplaces. As discussions around mental health become more commonplace, individuals are better informed about available treatment options, including antipsychotic medications. This increased awareness has empowered patients to actively engage with their healthcare providers and explore treatment options that best suit their needs.

Key Market Challenges

Adverse Side Effects

One of the primary challenges in the Antipsychotic Drugs market is the occurrence of adverse side effects associated with these medications. While second-generation antipsychotics have improved the side-effect profile compared to their predecessors, they can still lead to issues such as weight gain, metabolic disturbances, sedation, and sexual dysfunction. These side effects can significantly impact a patient's quality of life and treatment adherence. Weight gain, metabolic disturbances, sedation, and sexual dysfunction are common side effects associated with antipsychotic drugs, and these issues can significantly impact a patient's quality of life and treatment adherence. Weight gain and metabolic disturbances, including increased risk of diabetes and high cholesterol, not only affect physical health but also contribute to emotional distress for patients. Sedation can lead to daytime drowsiness and impaired cognitive function, making it challenging for individuals to maintain their daily routines. Sexual dysfunction, often a sensitive and stigmatized issue, can strain relationships and lead to decreased treatment compliance.

Treatment Non-Adherence

Antipsychotic medications often require long-term or even lifelong use to effectively manage mental health conditions. However, some patients may struggle with adherence due to side effects, the belief that they are 'cured' after initial improvement, or concerns about stigma. Non-adherence can lead to relapses and worsening of symptoms, posing a challenge to treatment effectiveness. When patients do not consistently take their prescribed antipsychotic medications, the effectiveness of these drugs is compromised, leading to potential relapses, hospitalizations, and a reduced quality of life. Several factors contribute to non-adherence. Side effects, as mentioned previously, can deter patients from taking their medications regularly. Moreover, the stigma surrounding mental health conditions and antipsychotic medications can lead some individuals to discontinue treatment discreetly. The complexity of medication regimens, especially for those on multiple drugs, can also be a barrier. Additionally, when patients begin to feel better, they may mistakenly believe they no longer need medication, leading to abrupt discontinuation. This is especially concerning since sudden cessation can result in withdrawal symptoms or a rapid return of psychiatric symptoms.

Cost of Medications

The high cost of some antipsychotic drugs can be a significant barrier to access for many patients, especially in regions without comprehensive healthcare coverage. These medications can represent a substantial financial burden for individuals and families, potentially limiting their ability to maintain consistent treatment. Antipsychotic drugs are often prescribed for the long-term or even lifelong management of conditions like schizophrenia and bipolar disorder. The ongoing expense of these medications can place a considerable financial burden on patients and their families. As a result, some individuals may struggle to afford their prescriptions, leading to non-adherence and interruptions in treatment that can have serious consequences for their mental health. Addressing the cost-related barriers to accessing antipsychotic drugs is essential to ensure that individuals with severe mental health conditions receive the treatment they need. This includes exploring options for generic or more affordable versions of these medications, as well as advocating for better insurance coverage and healthcare policies that make these vital treatments more accessible to all.

Key Market Trends

Personalized Medicine Approach

Personalized medicine is increasingly shaping the Antipsychotic Drugs market. Treatment plans are becoming more tailored to individual patient needs, considering factors such as genetics, side-effect profiles, and treatment response. Pharmacogenomic research is helping healthcare providers identify the most suitable antipsychotic medication and dosage for each patient, optimizing treatment efficacy while minimizing adverse effects. This patient-centric approach aligns with the broader trend in healthcare towards individualized care, fostering greater patient satisfaction and treatment adherence. Pharmacogenomic research plays a pivotal role in this trend by identifying the most suitable antipsychotic medication and dosage for each patient. By analyzing an individual's genetic makeup, healthcare providers can predict how a patient is likely to respond to a particular drug and whether they may be more prone to certain side effects. This information allows for the selection of the most appropriate medication from the outset, reducing the need for trial-and-error approaches and minimizing the risk of adverse effects.

Government Support and Healthcare Policies

Governments and healthcare organizations have recognized the significance of addressing mental health and have implemented policies and initiatives to promote well-being, increase access to treatment, and offer education and resources to the public. These efforts ensure that individuals with severe mental health conditions receive the necessary support and medication, further driving the demand for antipsychotic drugs. Government-funded mental health programs and initiatives help reduce the stigma associated with mental health conditions, encouraging individuals to seek help and treatment openly.

Furthermore, comprehensive healthcare coverage and reimbursement policies ensure that individuals with severe mental health conditions can access essential medications, such as antipsychotic drugs, without facing prohibitive costs. This financial support makes these vital treatments accessible to a broader segment of the population.

Segmental Insights

Application Insights

Based on the application, the Schizophrenia segment emerged as the dominant player in the global market for Antipsychotic Drugs Market in 2022 and is anticipated to grow in the forecast period. This is attributed to the persistently high prevalence of

schizophrenia worldwide. Schizophrenia is a severe and chronic mental health disorder that often requires long-term treatment with antipsychotic drugs to manage its symptoms effectively. Moreover, Schizophrenia is one of the most prevalent and debilitating mental health disorders globally, affecting millions of individuals. The chronic nature of the illness necessitates continuous medication management, which results in a consistent demand for antipsychotic drugs.

Drug Classification Insights

Based on the Drug Classification, the Second-Generation segment emerged as the dominant player in the global market for Antipsychotic Drugs Market in 2022. This is attributed to the superior efficacy and improved side-effect profiles of second-generation antipsychotic drugs. second-generation antipsychotics, often referred to as atypical antipsychotics, have been widely recognized for their ability to effectively manage the symptoms of severe mental health conditions like schizophrenia, bipolar disorder, and major depressive disorder.

Regional Insights

North America emerged as the dominant player in the global Antipsychotic Drugs Market in 2022, holding the largest market share. This is on account of several key factors such as North America has witnessed a significant prevalence of mental health disorders, including schizophrenia, bipolar disorder, and major depressive disorder. North America boasts a robust pharmaceutical industry with substantial investments in research and development. This has resulted in the development of innovative antipsychotic drugs with improved efficacy and safety profiles. The availability of cutting-edge treatments has fueled the demand for these medications within the region.

Key Market Players

Eli Lilly and Company

AstraZeneca plc

GlaxoSmithKline plc

Johnson & Johnson

Otsuka Pharmaceutical Co, Ltd.

Pfizer Inc.

AbbVie Inc.

Dr. Reddy's Laboratories Limited

Otsuka Holdings Co., Ltd.

Teva Pharmaceutical Industries Ltd

Report Scope:

In this report, the Global Antipsychotic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antipsychotic Drugs Market, By Application:

Schizophrenia

Bipolar Disorder

Unipolar Disorder

Dementia

Others

Antipsychotic Drugs Market, By Drug Classification:

First Generation (Typical)

Second Generation (Atypical))

Antipsychotic Drugs Market Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Turkey

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antipsychotic Drugs Market.

Available Customizations:

Global Antipsychotic Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL ANTIPSYCHOTIC DRUGS MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Application(Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, Others)
 - 5.2.2. By Drug Classification(First Generation (Typical), Second Generation (Atypical))
 - 5.2.3. By Company (2022)

- 5.2.4. By Region
- 5.3. Market Map

6. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Application
 - 6.2.2. By Drug Classification
 - 6.2.3. By Country
- 6.3. North America: Country Analysis
 - 6.3.1. United States Antipsychotic Drugs Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Application
 - 6.3.1.2.2. By Drug Classification
 - 6.3.2. Mexico Antipsychotic Drugs Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Application
 - 6.3.2.2.2. By Drug Classification
 - 6.3.3. Canada Antipsychotic Drugs Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Application
 - 6.3.3.2.2. By Drug Classification

7. EUROPE ANTIPSYCHOTIC DRUGS MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Application
 - 7.2.2. By Drug Classification
 - 7.2.3. By Country

7.3. Europe: Country Analysis

7.3.1. France Antipsychotic Drugs Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Tumor Type

7.3.1.2.2. By Drug Classification

7.3.2. Germany Antipsychotic Drugs Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Application

7.3.2.2.2. By Drug Classification

7.3.3. United Kingdom Antipsychotic Drugs Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Application

7.3.3.2.2. By Drug Classification

7.3.4. Italy Antipsychotic Drugs Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Application

7.3.4.2.2. By Drug Classification

7.3.5. Spain Antipsychotic Drugs Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Tumor Type

7.3.5.2.2. By Drug Classification

8. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Application

8.2.2. By Drug Classification

8.2.3. By Country

8.3. Asia-Pacific: Country Analysis

8.3.1. China Antipsychotic Drugs Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Tumor Type

8.3.1.2.2. By Drug Classification

8.3.2. India Antipsychotic Drugs Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Application

8.3.2.2.2. By Drug Classification

8.3.3. South Korea Antipsychotic Drugs Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Application

8.3.3.2.2. By Drug Classification

8.3.4. Japan Antipsychotic Drugs Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Application

8.3.4.2.2. By Drug Classification

8.3.5. Australia Antipsychotic Drugs Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Application

8.3.5.2.2. By Drug Classification

9. SOUTH AMERICA ANTIPSYCHOTIC DRUGS MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Application

- 9.2.2. By Drug Classification
- 9.2.3. By Country
- 9.3. South America: Country Analysis
 - 9.3.1. Brazil Antipsychotic Drugs Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Application
 - 9.3.1.2.2. By Drug Classification
 - 9.3.2. Argentina Antipsychotic Drugs Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Application
 - 9.3.2.2.2. By Drug Classification
 - 9.3.3. Colombia Antipsychotic Drugs Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Application
 - 9.3.3.2.2. By Drug Classification

10. MIDDLE EAST AND AFRICA ANTIPSYCHOTIC DRUGS MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Application
 - 10.2.2. By Drug Classification
 - 10.2.3. By Country
- 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Antipsychotic Drugs Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Application
 - 10.3.1.2.2. By Drug Classification
 - 10.3.2. Saudi Arabia Antipsychotic Drugs Market Outlook
 - 10.3.2.1. Market Size & Forecast

- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Application
 - 10.3.2.2.2. By Drug Classification
- 10.3.3. UAE Antipsychotic Drugs Market Outlook
 - 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
 - 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Application
 - 10.3.3.2.2. By Drug Classification

11. MARKET DYNAMICS

- 11.1. Drivers
- 11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions

13. PESTLE ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product

15. COMPETITIVE LANDSCAPE

- 15.1. Business Overview
- 15.2. Company Snapshot
- 15.3. Products & Services
- 15.4. Financials (In case of listed companies)
- 15.5. Recent Developments

15.6. SWOT Analysis

15.6.1. Eli Lilly and Company

15.6.2. AstraZeneca plc

15.6.3. GlaxoSmithKline plc

15.6.4. Johnson & Johnson

15.6.5. Otsuka Pharmaceutical Co, Ltd.

15.6.6. Pfizer Inc.

15.6.7. AbbVie Inc.

15.6.8. Dr. Reddy's Laboratories Limited

15.6.9. Otsuka Holdings Co., Ltd.

15.6.10. Teva Pharmaceutical Industries Ltd.

16. STRATEGIC RECOMMENDATIONS

I would like to order

Product name: Antipsychotic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Application (Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, Others), By Drug Classification(First Generation (Typical), Second Generation (Atypical)) By Company (2022) By Region and Competition

Product link: <https://marketpublishers.com/r/AFC25D1FCFCCEN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AFC25D1FCFCCEN.html>